Yuxiong Jiang

No. 301 Middle Yanchang Road
Shanghai, 200072, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Clinical predictors of early treatment response across systemic therapies in psoriasis: a prospective cohort study.

Clinical predictors of early treatment response across systemic therapies in psoriasis: a prospective cohort study.

Journal: The Journal of dermatological treatment

Published: August 13, 2026

Development of Predictive Models for NB-UVB Treatment Efficacy and Safety in Psoriasis.

Development of Predictive Models for NB-UVB Treatment Efficacy and Safety in Psoriasis.

Journal: Psoriasis (Auckland, N.Z.)

Published: March 17, 2026

Development and validation of a prediction model for primary non-response to IL-17A inhibitors in psoriasis.

Development and validation of a prediction model for primary non-response to IL-17A inhibitors in psoriasis.

Journal: Frontiers in medicine

Published: November 10, 2025

Differential clinical factors influencing the effectiveness of distinct biologic agents in psoriasis: insights from a prospective cohort study in China.

Differential clinical factors influencing the effectiveness of distinct biologic agents in psoriasis: insights from a prospective cohort study in China.

Journal: Inflammation research : official journal of the European Histamine Research Society ... [et al.]

Published: September 23, 2025

Higher body weight in Chinese patients is associated with treatment resistance to fixed-dose interleukin-17 inhibition with ixekizumab but not to weight-adjusted secukinumab therapy.

Higher body weight in Chinese patients is associated with treatment resistance to fixed-dose interleukin-17 inhibition with ixekizumab but not to weight-adjusted secukinumab therapy.

Journal: Journal of the American Academy of Dermatology

Published: September 13, 2025

Piezo1 exacerbates psoriasis by promoting macrophage M1 polarization and inhibits autophagy via activating PI3K/AKT signaling pathway.

Piezo1 exacerbates psoriasis by promoting macrophage M1 polarization and inhibits autophagy via activating PI3K/AKT signaling pathway.

Journal: Inflammation research : official journal of the European Histamine Research Society ... [et al.]

Published: July 22, 2025

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Journal: Drugs

Published: July 17, 2025

Generalized Actinic Granuloma After Prolonged Heat Exposure Improving With Baricitinib: A Case Report and Review of the Literature.

Generalized Actinic Granuloma After Prolonged Heat Exposure Improving With Baricitinib: A Case Report and Review of the Literature.

Journal: The Journal of dermatology

Published: July 06, 2025

Cryptochrome 2 stabilization alleviates psoriasis by inhibiting keratinocyte hyperproliferation and inflammation.

Cryptochrome 2 stabilization alleviates psoriasis by inhibiting keratinocyte hyperproliferation and inflammation.

Journal: International immunopharmacology

Published: July 03, 2025

Baseline Th17/Tc17 and LAG-3 levels serve as candidate exploratory markers for early ixekizumab response in psoriasis.

Baseline Th17/Tc17 and LAG-3 levels serve as candidate exploratory markers for early ixekizumab response in psoriasis.

Journal: Frontiers in immunology

Published: June 24, 2025

Positive associations between triglyceride-glucose (TyG) and TyG-body mass index (TyG-BMI) with cardiovascular disease in patients with psoriasis: cross-sectional results from the SPEECH.

Positive associations between triglyceride-glucose (TyG) and TyG-body mass index (TyG-BMI) with cardiovascular disease in patients with psoriasis: cross-sectional results from the SPEECH.

Journal: Frontiers in immunology

Published: June 11, 2025

Evaluating the Role of Disease Duration in Systemic Therapy Response Among Patients with Moderate-to-Severe Psoriasis.

Evaluating the Role of Disease Duration in Systemic Therapy Response Among Patients with Moderate-to-Severe Psoriasis.

Journal: Psoriasis (Auckland, N.Z.)

Published: June 04, 2025

Showing 1-12 of 35

Last Updated: 09/26/2026